Kineta Enters Into $5 Million Agreement With TuHURA Biosciences for Vista Blocking Immunotherapy; Shares Rise
Kineta (KA) said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, patent rights, patent applications, product and development program assets and other rights and assets linked to its Vista blocking immunotherapy program, KVA12123, for a nonrefundable payment of $5 million.
Express News | Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies
Express News | Kintara Therapeutics Inc - Under Terms of Agreement, Tuhura Will Pay Kineta $5.0 Mln
Express News | Kineta Inc: Kineta Will Receive a $5 Mln Nonrefundable Payment From Tuhura
Express News | Tuhura Biosciences Enters Into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s Kva12123 Novel Anti-Vista Checkpoint Inhibitor
Express News | Kineta Announces Exclusivity and Right of First Offer Agreement for Its Vista Blocking Antibody With Tuhura Biosciences
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeuti
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed ref
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersScinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:ND
12 Health Care Stocks Moving In Friday's After-Market Session
GainersKineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 1
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersVirax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37%
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwar
Express News | Kineta Inc: On May 23, Got Notice From Nasdaq That It No Longer Complies With Requirement Under Nasdaq Listing Rule 5550(B)(1)
Kineta | 10-Q: Quarterly report
Kineta 1Q Loss/Shr 89c >KA
Kineta 1Q Loss/Shr 89c >KA
Kineta 1Q Rev $0.00 >KA
Kineta 1Q Rev $0.00 >KA
Express News | Kineta Inc Q1 EPS $-0.89
Express News | Kineta Says Actively Exploring Strategic Alternatives To Maximize Value For All Stakeholders
Express News | Kineta Exploring Strategic Alternatives for Stakeholders
No Data